Novartis (NYSE: NVS) Receives FDA Approval for Extavia

Novartis AG (ADR NYSE: NVS) recently announced the US Food and Drug Administration (FDA) has approved Extavia, the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease. Extavia is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging (MRI).

“Interferon is a mainstay of treatment in MS," said Doug Jeffery, MD, Associate Professor at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, USA. "With the approval of Extavia, patients have another option with a well-established safety and efficacy profile to help manage this disease."  "MS is unpredictable and can be difficult to manage," said Aaron Miller, MD, Professor of Neurology at Mount Sinai School of Medicine in New York, USA. "Support programs are an essential element to help patients and physicians effectively manage this complicated disease." "Novartis has been a leader in neuroscience for more than 50 years, having pioneered a number of breakthrough therapies which remain important treatments to this day," said Joe Jimenez, CEO of the Novartis Pharmaceuticals Division. "We are committed to providing new approaches to MS care, and the FDA approval of Extavia marks the beginning of our long-term commitment to the MS community in the US."

Extavia will be available to patients in the US this fall. Along with their prescription for Extavia, patients will be given access to a support program including a nurse helpline, one-on-one injection training and reimbursement support services. Extavia patients will have an autoinjector available to them from Novartis.

###

Click here for more Business News 

About The Global Market Directory (TheGMD) 

TheGMD provides an online global directory listing featuring public companies, stock brokers, brokerage firms and individuals.  The GMD provides profiles for Brokerage Firms, Stock Brokers and Individuals in addition to Public Companies. 

The GMD is a division of TransWorldNews, Inc. Companies can utilize the TransWorldNews press release distribution services and have all news releases attached to their GMD profile.

Create your profile on The Global Market Directory. Join The GMD and become a member of our expansive business network.